![]()
Ankle study by Drs. Philippe Hernigou and Christopher Centeno: 18.2% of ankles treated inside the bone needed fusion or replacement over 15 years vs. 50%
DALLAS, TX, UNITED STATES, November 19, 2026 /EINPresswire.com/ — For millions of Americans with osteoarthritis, the conversation usually centers on worn cartilage, pain management and, eventually, joint replacement. A newly published study is adding to a growing body of research on another part of the disease: the bone immediately beneath the cartilage.
The study, published September 3, 2026, in Medicina by French orthopedic surgeon and researcher Philippe Hernigou, MD, and coauthor Christopher Centeno, MD, examines intraosseous bone marrow concentrate (BMC) injections for ankle osteoarthritis. It builds on Hernigou’s earlier long-term knee research.
“Most patients think of osteoarthritis as cartilage wearing away,” says Deborah Westergaard, MD, double board-certified in Anesthesiology and Pain Medicine and Medical Director of Regen Experts in Dallas and Plano, Texas. “But the bone beneath that cartilage is living tissue. It can develop structural changes, inflammation and lesions that may contribute to pain and disease progression. If we are only looking at the cartilage, we may be missing an important part of the problem.”
New Ankle Study Published in 2026
The study followed 88 patients with osteoarthritis in both ankles. The more symptomatic ankle received intraosseous bone marrow concentrate, while the other ankle was managed without surgery. Over the 15-year analysis period, 18.2% of treated ankles underwent ankle fusion or replacement, compared with 50% of the comparison ankles.
Because the study was retrospective and treatment was not randomly assigned, it cannot establish that BMC caused the difference in surgical outcomes. It does extend this line of research beyond the knee.
Earlier Knee Research Laid the Groundwork
In a 2021 prospective randomized study by Hernigou and colleagues, 140 patients were scheduled for knee replacement in both knees. One knee underwent total knee replacement, while the other received bone marrow concentrate injected directly into the subchondral bone. At an average 15-year follow-up, about 18% of the BMC-treated knees (25 of 140) had gone on to knee replacement.
In a separate randomized study of 60 patients, 20% of knees treated within the bone underwent replacement at 15 years, compared with 70% of knees injected into the joint space, suggesting that where the treatment is placed may matter.
These studies do not establish that bone marrow injections can reliably prevent joint replacement, and additional independent research is needed.
What Is an Intraosseous Injection?
A conventional joint injection places material into the fluid-filled joint space. An intraosseous injection, performed under imaging guidance, delivers treatment directly into the bone beneath the joint surface, using bone marrow concentrate prepared from the patient’s own bone marrow.
Diagnosis Comes First
“An MRI can show cartilage loss, bone marrow lesions, meniscal damage and other abnormalities,” Dr. Westergaard explains. “But imaging alone does not tell us everything. I want to understand what hurts, what the examination shows, how the joint functions and what the patient wants to get back to doing.”
“Joint preservation does not mean avoiding surgery at all costs,” she adds. “It means understanding whether there is a reasonable opportunity to preserve useful anatomy and function before making an irreversible decision.”
Adults in North Texas with knee, hip, shoulder or ankle arthritis can schedule an evaluation, including a review of their actual MRI images, at Regen Experts’ Dallas or Plano office. Visit https://www.regenexpertsmd.com/request-an-appointment or call 214-750-6200.
About Regen Experts
Regen Experts is a physician-led spine and joint preservation practice serving Dallas, Plano and North Texas. Led by Deborah Westergaard, MD, with more than three decades of clinical experience, the practice emphasizes detailed diagnosis, image-guided precision and individualized nonoperative options. As a Regenexx-affiliated practice, Regen Experts evaluates patients for orthobiologic treatments, including platelet-rich plasma and autologous bone marrow concentrate, when clinically appropriate.
Medical disclosure: Intraosseous BMC for osteoarthritis remains investigational. The cited studies do not establish that treatment reliably regenerates cartilage, prevents surgery or produces equivalent outcomes across patients.
Published Research: Hernigou P, Centeno CJ, et al. Medicina. 2026. https://doi.org/10.3390/medicina62091693 | Hernigou P, et al. International Orthopaedics. 2021. https://pubmed.ncbi.nlm.nih.gov/32322943/ and https://pubmed.ncbi.nlm.nih.gov/32617651/
Deborah Westergaard, MD
Regen Experts
+1 214-750-6200
press@regenexpertsmd.com
Legal Disclaimer:
EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
![]()
Media gallery
